Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camiña, M. F.
Right arrow Articles by Rodriguez-Segade, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camiña, M. F.
Right arrow Articles by Rodriguez-Segade, S.
NEUROLOGY 1991;41:1444
© 1991 American Academy of Neurology

Alteration of renal carnitine metabolism by anticonvulsant treatment

M. F. Camiña, PhD, I. Rozas, PhD, M. Castro-Gago, MD, J. M. Paz, PhD, C. Alonso, PhD and S. Rodriguez-Segade, PhD

Department of Biochemistry (Faculty of Pharmacy) and Services of Neuropediatrics and Central Laboratory (Hospital General de Galicia), Universidad de Santiago de Compostela, Spain.

We administered therapeutic doses of valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), and phenobarbital (PHB) to mice for 7 days, and 8 hours after the final dose we measured the concentrations of carnitine in serum, liver, kidney, skeletal muscle, and heart, and in the 7 days' accumulated urine. The results for serum and urine show that VPA induced a significant increase in renal clearance of acylcarnitine without affecting that of free carnitine, whereas CBZ, PHT, and PHB significantly increased clearance of free carnitine but not that of acylcarnitine. Thus, VPA appears to reduce tubular resorption of acylcarnitine, and CBZ, PHT, and PHB appear to reduce tubular resorption of free carnitine.

Address correspondence and reprint requests to Dr. S. Rodriguez-Segade, Department of Biochemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain.

Supported by the Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS) of Spain.

Received October 9, 1990. Accepted for publication in final form February 25, 1991.




This article has been cited by other articles:


Home page
 J Am Board Fam MedHome page
J. Wadzinski, R. Franks, D. Roane, and M. Bayard
Valproate-associated Hyperammonemic Encephalopathy
J Am Board Fam Med, September 1, 2007; 20(5): 499 - 502.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
S. Kurul, E. Dirik, and A. IIscan
Serum Carnitine Levels During Oxcarbazepine and Carbamazepine Monotherapies in Children With Epilepsy
J Child Neurol, August 1, 2003; 18(8): 552 - 554.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
M. Castro-Gago, J. Eiris-Punal, M. I. Novo-Rodriguez, J. Couceiro, F. Camina, and S. Rodriguez-Segade
Serum Carnitine Levels in Epileptic Children Before and During Treatment With Valproic Acid, Carbamazepine, and Phenobarbital
J Child Neurol, November 1, 1998; 13(11): 546 - 549.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. L. Coulter
Carnitine Deficiency in Epilepsy: Risk Factors and Treatment
J Child Neurol, November 1, 1995; 10(2_suppl): 2S32 - 2S39.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by AAN Enterprises, Inc.